This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About ZEPATIER®▼ (elbasvir and grazoprevir)

Updated on 15/03/2018

HEPATITIS C

SIMPLE* POWER TO CURE** FOR CHRONIC HEPATITIS C1-9

Simple, power to cure banner

ZEPATIER is indicated for the treatment of chronic hepatitis C genotypes 1 and 4 infection in adults1

ZEPATIER 12 weeks achieved 95% SVR for treatment naïve patients’ image

*“simple” is supported by the information held on the DDIs and dosing simplicity page

**Cure of HCV infection = sustained virologic response (SVR), the primary endpoint in all studies, was defined as hepatitis C virus (HCV) ribonucleic acid (RNA) less than the lower limit of quantification (LLOQ) (=15 IU/ml) at 12 weeks after the cessation of treatment.1,11

References

  1. ZEPATIER summary of Product Characteristics.
  2. Dore GL et al, Ann Int Med 2016;doi:10.7326/M16-0816 [Epub ahead of print]
  3. Roth D et al. Lancet 2015:386:1537-1545.
  4. Rockstroh JK et al. Lancet HIV 2015:2(8);319-327.
  5. Zeuzem S et al. Ann Intern Med 2015; 163:1-13.
  6. Forns X et al. J Hepatol 2015;63:564-572.
  7. Kwo PY et al. C-EDGE TE EASL 2015.
  8. Sperl J et al. Presented at EASL April 13-17 2016; Barcelona Spain: Abstract PS002.
  9. Jacobson IM et al. Presented at: 66th Annual Meeting of the American Association for the Study of Liver Diseases; November 13-17 2015; Boston, MA.
  10. Europena Association for the Study of the Liver. J Hepatol 2015;63:199-236.

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

INFC-1247325-0000 | Date of Preparation: March 2018